secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2026-06-01T20:22:15+00:00
Accession:  0001628280-26-039518
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion shareholders approve 7M-share increase to 2022 equity incentive plan
-----------------------------------------------------------------------------

- Stockholders approved Plan Amendment increasing 2022 Plan authorized shares by 7,000,000.
- J. Martin Carroll and Sheldon L. Koenig elected as Class I directors for terms ending 2029.
- Advisory vote on executive compensation approved with ~95.7M for, ~34.9M against.
- Ratification of Ernst & Young as auditor for FY2026 passed with ~167.1M for.
- All proposals passed at May 28, 2026 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/espr-20260528.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-039518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer